Ironwood Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Ironwood Pharmaceuticals reports a decrease in 2025 collaborative revenue for LINZESS due to pricing and inventory shifts, while advancing its apraglutide program despite a required confirmatory Phase III trial.
NASDAQ
Ironwood Pharmaceuticals' 2024 results show a decrease in LINZESS revenue but progress in its pipeline, particularly with apraglutide.
NASDAQ
10-K: Ironwood Pharmaceuticals 2023 10-K Filing: Focus on LINZESS, Apraglutide, and Strategic Growth
Ironwood Pharmaceuticals' 2023 10-K filing highlights the company's focus on maximizing LINZESS, advancing its GI pipeline, and delivering sustained profits and cash flow, including the acquisition of VectivBio and progress on apraglutide.